Uluru Co., Ltd. (3979) AI Stock Analysis

• Market Cap: ¥11.52B
• Dividend Yield: 2.44%
• Average Volume (3M): 19.50K
• Price to Earnings (P/E): 18.8
• Beta (1Y): 0.43
• Revenue Growth: 12.77%
• EPS Growth: -1.50%
• Country: JP
• Employees: 140
• Sector: Technology
• Sector Strength: 88
• Industry: Information Technology Services
• EPS (TTM): 6.96
• Shares Outstanding: 27,701,600
• 10 Day Avg. Volume: 13,720
• 30 Day Avg. Volume: 19,503
• PEG Ratio: -0.30
• Price to Book (P/B): 3.81
• Price to Sales (P/S): 1.72
• P/FCF Ratio: 22.63
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 75 Outperform
• Price Target: ¥460.00 ▲(10.05% Upside)

Uluru Co., Ltd. demonstrates strong financial performance with robust revenue growth and efficient cash flow management, contributing significantly to the overall score. The stock's valuation is reasonable, with a decent dividend yield. However, technical indicators suggest a lack of strong upward momentum, which slightly dampens the overall score.

Uluru Co., Ltd. Business Overview & Revenue Model

Company Description

Uluru Co., Ltd. (3979) is a Japanese company primarily engaged in the development and commercialization of innovative pharmaceutical products, particularly focusing on regenerative medicine and drug delivery systems. The company operates within the biotechnology sector, leveraging advanced technologies to create therapies that address unmet medical needs. Its core offerings include proprietary products designed for the treatment of various diseases, alongside a range of research and development services aimed at enhancing the efficacy and safety of pharmaceuticals.

How the Company Makes Money

Uluru Co., Ltd. generates revenue through multiple channels, primarily from the sales of its pharmaceutical products and services. The company’s key revenue streams include direct sales of its proprietary medications, licensing agreements with other pharmaceutical firms for the use of its technologies, and partnerships with research institutions for joint development projects. Additionally, Uluru may benefit from milestone payments and royalties as part of its collaborations with larger healthcare companies, which can significantly contribute to its earnings. The company's focus on innovative treatment solutions and strategic alliances plays a critical role in enhancing its market position and driving financial growth.

Uluru Co., Ltd. Financial Statement Overview

Summary

Uluru Co., Ltd. exhibits a robust financial profile with strong revenue growth and efficient cash flow management. The company maintains a stable balance sheet with low leverage, although challenges in profitability and declining return on equity highlight areas for improvement.

Income Statement

Uluru Co., Ltd. has consistently demonstrated strong revenue growth, with an impressive revenue growth rate of 12.85% from 2024 to 2025. The gross profit margin stands at 69.78%, indicating efficient cost management. However, a decline in EBIT and net profit margins suggests potential challenges in operational efficiency and profitability.

Balance Sheet

The company maintains a healthy equity position with an equity ratio of 48.51% and a low debt-to-equity ratio of 0.05, reflecting strong financial stability. However, the return on equity has decreased to 15.13%, indicating a need for better utilization of equity capital to generate profits.

Cash Flow

Uluru Co., Ltd. has achieved positive free cash flow of 509.35 million, demonstrating strong cash generation capabilities. The operating cash flow to net income ratio is 1.42, indicating effective cash operations. However, the significant reduction in free cash flow growth rate from the previous year signals potential challenges in sustaining cash flow levels.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	6.91B	6.70B	5.94B	4.86B	4.03B	3.22B
Gross Profit	4.87B	4.68B	4.25B	3.49B	2.84B	2.24B
EBITDA	990.74M	937.14M	1.35B	103.33M	-174.09M	199.50M
Net Income	601.99M	458.07M	720.11M	-45.51M	-64.40M	42.20M
Balance Sheet
Total Assets	6.50B	6.24B	6.05B	4.62B	4.34B	4.20B
Cash, Cash Equivalents and Short-Term Investments	3.69B	3.41B	3.59B	2.40B	2.81B	3.29B
Total Debt	148.33M	158.33M	198.33M	38.88M	80.69M	123.01M
Total Liabilities	3.35B	3.21B	3.24B	2.53B	2.21B	1.99B
Stockholders Equity	3.15B	3.03B	2.81B	2.09B	2.13B	2.21B
Cash Flow
Free Cash Flow	389.00M	509.35M	1.10B	41.92M	-105.49M	643.99M
Operating Cash Flow	532.00M	651.91M	1.47B	328.86M	-30.70M	701.83M
Investing Cash Flow	-420.00M	-553.08M	-441.29M	-695.05M	-416.77M	-196.43M
Financing Cash Flow	-154.00M	-283.60M	160.11M	-42.85M	-39.20M	-78.59M

Uluru Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 418.00
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:3979, the sentiment is Negative. The current price of 418 is below the 20-day moving average (MA) of 421.32, above the 50-day MA of 416.05, and above the 200-day MA of 400.20, indicating a neutral trend. The MACD of -2.23 indicates Positive momentum. The RSI at 42.92 is Neutral, neither overbought nor oversold. The STOCH value of 43.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:3979.

Uluru Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2332	80 Outperform	¥8.16B	11.19	―	3.10%	9.60%	2.11%
3979	75 Outperform	¥11.52B	18.79	―	2.44%	12.77%	-1.50%
3918	73 Outperform	¥12.01B	10.49	―	3.51%	-7.36%	35.89%
3940	72 Outperform	¥6.16B	15.17	―	2.46%	8.71%	4.70%
4398	65 Neutral	¥6.19B	42.63	―	1.08%	-5.47%	-68.77%
Sector *	61 Neutral	$37.18B	12.37	-10.20%	1.83%	8.50%	-7.62%
4056	52 Neutral	¥8.90B	175.56	―	―	4.41%	―

Uluru Co., Ltd. Corporate Events

Uluru Co., Ltd. Reports Strong Q1 Results and Announces Stock Split

Uluru Co., Ltd. reported a strong financial performance for the first quarter of the fiscal year ending March 31, 2026, with significant increases in net sales and profits compared to the previous year. The company also announced a planned 4-for-1 stock split effective October 1, 2025, which is expected to impact dividend calculations and shareholder benefits, reflecting a strategic move to enhance shareholder value.

The most recent analyst rating on (JP:3979) stock is a Buy with a Yen1763.00 price target. To see the full list of analyst forecasts on Uluru Co., Ltd. stock, see the JP:3979 Stock Forecast page.